| scholarly article | Q13442814 |
| P50 | author | Katherine A. High | Q41502889 |
| P2093 | author name string | Hua Li | |
| Hildegund C J Ertl | |||
| Weidong Xiao | |||
| Dongming Zhou | |||
| Te-Lang Wu | |||
| Wynetta Giles-Davis | |||
| Steven Tuyishime | |||
| P2860 | cites work | Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy | Q41999615 |
| Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets | Q42613058 | ||
| Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination | Q43725424 | ||
| CD8(+) T-cell responses to adeno-associated virus capsid in humans | Q45406111 | ||
| Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector | Q45855552 | ||
| Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector | Q45862203 | ||
| Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes | Q45865401 | ||
| Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy | Q45884700 | ||
| Challenges of immune responses in gene replacement therapy. | Q51989357 | ||
| Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles | Q56897778 | ||
| Identification of conserved T cell receptor CDR3 residues contacting known exposed peptide side chains from a major histocompatibility complex class I-bound determinant | Q57082205 | ||
| Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1 | Q24634560 | ||
| In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens | Q29615098 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| Identification of mouse AAV capsid-specific CD8+ T cell epitopes | Q33226431 | ||
| Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles | Q33337378 | ||
| A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer | Q33713730 | ||
| A prescription for human immunology | Q34001827 | ||
| Antigen decoding by T lymphocytes: from synapses to fate determination | Q34263452 | ||
| Self-complementary AAV vectors; advances and applications | Q34804660 | ||
| Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo | Q35914452 | ||
| The proteasome and MHC class I antigen processing | Q35967572 | ||
| Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice | Q36144935 | ||
| New recombinant serotypes of AAV vectors. | Q36172991 | ||
| Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. | Q36438711 | ||
| Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses | Q36685842 | ||
| Immune responses to AAV in clinical trials | Q36990095 | ||
| Cellular immune response to cryptic epitopes during therapeutic gene transfer | Q37250034 | ||
| AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells | Q37348251 | ||
| Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy | Q37364038 | ||
| Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses | Q37712554 | ||
| Antigen presenting cells | Q38644205 | ||
| Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses | Q39501488 | ||
| Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo | Q39860625 | ||
| P433 | issue | 3 | |
| P921 | main subject | vector-borne disease | Q2083837 |
| P304 | page(s) | 536-546 | |
| P577 | publication date | 2010-12-14 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice | |
| P478 | volume | 19 |
| Q37690476 | CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome. |
| Q35568563 | Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates |
| Q36595639 | Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy |
| Q47554736 | Emerging Issues in AAV-Mediated In Vivo Gene Therapy |
| Q36709834 | Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. |
| Q57803544 | Exposure to wild-type AAV drives distinct capsid immunity profiles in humans |
| Q36295934 | Gene Therapy for Duchenne muscular dystrophy |
| Q92863312 | Immune Response Mechanisms against AAV Vectors in Animal Models |
| Q36983740 | Immune responses to AAV vectors: overcoming barriers to successful gene therapy |
| Q36848699 | Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical |
| Q39553052 | Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia |
| Q41907025 | Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes |
| Q92940638 | Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans |
| Q38191212 | Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors |
| Q61811175 | Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy |
| Q40282843 | Regulatory and Exhausted T Cell Responses to AAV Capsid. |
| Q24625426 | Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome |
| Q40458807 | Synergistic inhibition of PARP-1 and NF-κB signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy. |
| Q36155013 | The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing |
| Q96109656 | Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates |
| Q36143384 | Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates |
| Q95271852 | Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A |
| Q40073271 | Unraveling the complex story of immune responses to AAV vectors trial after trial |
Search more.